US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MBX Biosciences

37.67

+1.624.49%

Post-market: 37.62-0.0500-0.13%19:19 EST

Volume:345.36K

Turnover:12.97M

Market Cap:1.69B

PE:-15.75

High:38.12

Open:36.77

Low:36.63

Close:36.05

52wk High:44.89

52wk Low:4.81

Shares:44.90M

Float Shares:25.72M

Volume Ratio:0.31

T/O Rate:1.34%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-2.3917

EPS(LYR):-5.8181

ROE:-24.43%

ROA:-16.64%

PB:4.36

PE(LYR):-6.47

Loading ...

Overview Company News Filings

MBX Biosciences Raises $87 Million in ATM Offering

Microbix to Release Q1 2026 Results and Host Investor Webinar on February 12

MBX Biosciences Initiated at Overweight by Barclays

MBX Biosciences initiated with an Overweight at Barclays

MBX Biosciences Appoints Laurie Stelzer as Board Director and Audit Committee Chair

Is MBX Biosciences’ (MBX) Once‑Monthly Obesity Strategy Quietly Redefining Its Competitive Moat?

Simply Wall St.

MBX Biosciences Is Maintained at Buy by Guggenheim

Nasdaq Net Change Percentage Gainers & Losers

MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy

MBX Biosciences, Inc. (MBX) Receives a Buy from Stifel Nicolaus

MBX Biosciences provides update on clinical programs

BRIEF-Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026

MBX Biosciences Projects Cash Reserves Will Fund Operations Into 2029

Mbx Biosciences Inc - Phase 3 Trial of Canvuparatide to Start in Q3 2026

THOMSON REUTERS

Mbx Biosciences to Provide 2026 Outlook and Business Update at 44TH Annual J.p. Morgan Healthcare Conference

THOMSON REUTERS

Mbx Biosciences Inc - Two New Obesity Candidates to Be Nominated in 2026

THOMSON REUTERS

MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference

Is UBS’s Canvuparatide Focus Altering The Investment Case For MBX Biosciences (MBX)?

Simply Wall St.

Microbix Tightens EBITDA Disclosure After OSC Review

MBX Biosciences Initiated at Buy by UBS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/MBX/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"MBX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","market":"US","secType":"STK","nameCN":"MBX Biosciences","latestPrice":37.67,"timestamp":1770411600000,"preClose":36.05,"halted":0,"volume":345355,"hourTrading":{"tag":"盘后","latestPrice":37.62,"preClose":37.67,"latestTime":"19:19 EST","volume":16261,"amount":612440.62,"timestamp":1770423583511,"change":-0.05,"changeRate":-0.001327,"amplitude":0.003716},"delay":0,"changeRate":0.04493758668515963,"floatShares":25718200,"shares":44902302,"eps":-2.391686,"marketStatus":"Market Closed","change":1.62,"latestTime":"02-06 16:00:00 EST","open":36.77,"high":38.12,"low":36.63,"amount":12968596.555725,"amplitude":0.041331,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-2.391686,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1770627600000},"marketStatusCode":7,"adr":0,"listingDate":1726200000000,"exchange":"NASDAQ","adjPreClose":36.05,"preHourTrading":{"tag":"盘前","latestPrice":36.05,"preClose":36.05,"latestTime":"09:13 EST","volume":6,"amount":220.400004,"timestamp":1770387215232,"change":0,"changeRate":0,"amplitude":0.0319},"postHourTrading":{"tag":"盘后","latestPrice":37.62,"preClose":37.67,"latestTime":"19:19 EST","volume":16261,"amount":612440.62,"timestamp":1770423583511,"change":-0.05,"changeRate":-0.001327,"amplitude":0.003716},"volumeRatio":0.3098881188660124,"impliedVol":0.9678,"impliedVolPercentile":0.311},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"MBX\",,,,,undefined,":{"symbol":"MBX","floatShares":25718200,"roa":"-16.64%","roe":"-24.43%","lyrEps":-5.818121,"volumeRatio":0.3098881188660124,"shares":44902302,"dividePrice":0,"high":38.12,"amplitude":0.041331,"preClose":36.05,"low":36.63,"week52Low":4.8069,"pbRate":"4.36","week52High":44.89,"institutionHeld":0,"latestPrice":37.67,"eps":-2.391686,"divideRate":0,"volume":345355,"delay":0,"ttmEps":-2.391686,"open":36.77,"prevYearClose":31.54,"prevWeekClose":36.85,"prevMonthClose":36.85,"prevQuarterClose":31.54,"fiveDayClose":36.85,"twentyDayClose":30.72,"sixtyDayClose":24.49},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/MBX\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-11-06","symbol":"MBX","fiscalQuarterEnding":"2025/09","expectedEps":-0.73,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1762405200000,"reportTimeType":"pre","actualEps":-0.63},{"market":"US","date":"2025-08-07","symbol":"MBX","fiscalQuarterEnding":"2025/06","expectedEps":-0.77,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1754539200000,"reportTimeType":"pre","actualEps":-0.58},{"market":"US","date":"2025-05-12","symbol":"MBX","fiscalQuarterEnding":"2025/03","expectedEps":-0.81,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1747022400000,"reportTimeType":"pre","actualEps":-0.71},{"market":"US","date":"2025-03-17","symbol":"MBX","fiscalQuarterEnding":"2024/12","expectedEps":-0.59,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1742184000000,"reportTimeType":"pre","actualEps":-0.47}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"MBX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"MBX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.3636,"buy":0.5455,"hold":0,"sell":0.0909,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5455,"analysts":11,"updateTime":1769576400000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/MBX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"MBX","date":"2026-02-05","current":-15.750395,"percent":0.022792,"low":-24.064666,"twenty":-15.958314,"median":-7.92198,"eighty":-5.355906,"high":-3.125337,"avg":-10.036736,"sd":5.288044,"marketCap":1722901327},"quantilePoints":[{"date":"2024-09-13","current":-15.960592,"twenty":-13.895501,"median":-10.797864,"eighty":-10.797864,"marketCap":753339957},{"date":"2024-09-20","current":-15.949203,"twenty":-15.694582,"median":-15.111074,"eighty":-12.419885,"marketCap":752802389},{"date":"2024-09-27","current":-16.939398,"twenty":-16.33255,"median":-15.751164,"eighty":-14.917986,"marketCap":799539567},{"date":"2024-10-04","current":-16.797941,"twenty":-16.986079,"median":-16.110499,"eighty":-15.091977,"marketCap":792862827},{"date":"2024-10-11","current":-16.932325,"twenty":-16.986079,"median":-16.31699,"eighty":-15.248994,"marketCap":799205730},{"date":"2024-10-18","current":-17.024271,"twenty":-17.032759,"median":-16.518565,"eighty":-15.369232,"marketCap":803545610},{"date":"2024-10-25","current":-15.022664,"twenty":-17.021442,"median":-16.380645,"eighty":-15.369232,"marketCap":709069745},{"date":"2024-11-01","current":-15.885548,"twenty":-16.991737,"median":-16.362963,"eighty":-15.369232,"marketCap":749797857},{"date":"2024-11-08","current":-13.874718,"twenty":-16.947885,"median":-16.309917,"eighty":-15.248994,"marketCap":765593046},{"date":"2024-11-15","current":-10.66494,"twenty":-16.936569,"median":-16.143706,"eighty":-14.480386,"marketCap":588480730},{"date":"2024-11-22","current":-11.203941,"twenty":-16.918179,"median":-15.949203,"eighty":-13.805677,"marketCap":618222233},{"date":"2024-11-29","current":-12.318278,"twenty":-16.877157,"median":-15.751164,"eighty":-12.380051,"marketCap":679710282},{"date":"2024-12-06","current":-13.432616,"twenty":-16.771064,"median":-15.461179,"eighty":-11.837418,"marketCap":741198331},{"date":"2024-12-13","current":-11.470413,"twenty":-16.663558,"median":-15.31265,"eighty":-11.837418,"marketCap":632925896},{"date":"2024-12-20","current":-12.330391,"twenty":-16.662143,"median":-15.019127,"eighty":-11.803503,"marketCap":680378630},{"date":"2024-12-27","current":-12.154761,"twenty":-16.656485,"median":-14.542475,"eighty":-11.803503,"marketCap":670687579},{"date":"2025-01-03","current":-11.258446,"twenty":-16.435813,"median":-14.054537,"eighty":-11.676323,"marketCap":621229800},{"date":"2025-01-10","current":-8.290916,"twenty":-16.380645,"median":-13.850493,"eighty":-11.492215,"marketCap":457484452},{"date":"2025-01-17","current":-5.989566,"twenty":-16.372157,"median":-13.75965,"eighty":-11.117943,"marketCap":330498264},{"date":"2025-01-24","current":-6.510398,"twenty":-16.36367,"median":-13.256987,"eighty":-10.797864,"marketCap":359237243},{"date":"2025-01-31","current":-6.06224,"twenty":-16.342452,"median":-12.878476,"eighty":-9.893382,"marketCap":334508354},{"date":"2025-02-07","current":-7.473331,"twenty":-16.314161,"median":-12.457571,"eighty":-8.809325,"marketCap":412370938},{"date":"2025-02-14","current":-6.304488,"twenty":-16.290113,"median":-12.324334,"eighty":-7.444262,"marketCap":347875321},{"date":"2025-02-21","current":-6.589128,"twenty":-16.247676,"median":-12.215323,"eighty":-7.171733,"marketCap":363581507},{"date":"2025-02-28","current":-5.813937,"twenty":-16.175534,"median":-12.009413,"eighty":-6.798672,"marketCap":320807212},{"date":"2025-03-07","current":-5.989566,"twenty":-16.064646,"median":-11.803503,"eighty":-6.591551,"marketCap":330498264},{"date":"2025-03-14","current":-5.26888,"twenty":-15.958314,"median":-11.682379,"eighty":-6.514032,"marketCap":290731536},{"date":"2025-03-21","current":-4.258879,"twenty":-15.936472,"median":-11.549143,"eighty":-6.294798,"marketCap":263718287},{"date":"2025-03-28","current":-4.188707,"twenty":-15.858671,"median":-11.258446,"eighty":-6.213645,"marketCap":259373118},{"date":"2025-04-04","current":-3.260282,"twenty":-15.749749,"median":-11.107042,"eighty":-6.057395,"marketCap":201883200},{"date":"2025-04-11","current":-3.999783,"twenty":-15.687509,"median":-10.797864,"eighty":-5.922948,"marketCap":247674589},{"date":"2025-04-17","current":-4.113138,"twenty":-15.461179,"median":-10.66494,"eighty":-5.686757,"marketCap":254693707},{"date":"2025-04-25","current":-4.949799,"twenty":-15.461179,"median":-9.901861,"eighty":-5.438453,"marketCap":306501482},{"date":"2025-05-02","current":-6.477382,"twenty":-15.454106,"median":-9.653557,"eighty":-5.327647,"marketCap":401092452},{"date":"2025-05-09","current":-5.996976,"twenty":-15.31265,"median":-8.539219,"eighty":-5.438453,"marketCap":371344761},{"date":"2025-05-16","current":-5.077465,"twenty":-15.206557,"median":-7.473331,"eighty":-5.077465,"marketCap":373015980},{"date":"2025-05-23","current":-5.691675,"twenty":-15.022664,"median":-7.246225,"eighty":-5.226487,"marketCap":418138881},{"date":"2025-05-30","current":-5.787218,"twenty":-15.017006,"median":-7.134185,"eighty":-5.260401,"marketCap":425157999},{"date":"2025-06-06","current":-5.395944,"twenty":-14.885451,"median":-6.813207,"eighty":-5.315894,"marketCap":396413040},{"date":"2025-06-13","current":-4.877278,"twenty":-14.35621,"median":-6.707223,"eighty":-5.172099,"marketCap":358309257},{"date":"2025-06-20","current":-4.677092,"twenty":-14.130289,"median":-6.595185,"eighty":-5.059804,"marketCap":343602533},{"date":"2025-06-27","current":-5.136611,"twenty":-14.052953,"median":-6.564904,"eighty":-5.017962,"marketCap":377361148},{"date":"2025-07-03","current":-5.673476,"twenty":-13.977856,"median":-6.515167,"eighty":-5.013234,"marketCap":416801906},{"date":"2025-07-11","current":-5.641628,"twenty":-13.855338,"median":-6.4303,"eighty":-5.035235,"marketCap":414462200},{"date":"2025-07-18","current":-5.548359,"twenty":-13.804466,"median":-6.320845,"eighty":-5.055522,"marketCap":407610204},{"date":"2025-07-25","current":-5.928259,"twenty":-13.766918,"median":-6.298431,"eighty":-5.072006,"marketCap":435519554},{"date":"2025-08-01","current":-6.028352,"twenty":-13.628836,"median":-6.310434,"eighty":-5.101123,"marketCap":442872915},{"date":"2025-08-08","current":-4.830149,"twenty":-13.362364,"median":-6.283291,"eighty":-5.101123,"marketCap":372013249},{"date":"2025-08-15","current":-5.76189,"twenty":-13.198847,"median":-6.22399,"eighty":-5.101123,"marketCap":443774969},{"date":"2025-08-22","current":-6.171895,"twenty":-13.089836,"median":-6.221845,"eighty":-5.14935,"marketCap":475353203},{"date":"2025-08-29","current":-6.224236,"twenty":-12.914207,"median":-6.224236,"eighty":-5.170279,"marketCap":479384467},{"date":"2025-09-05","current":-5.635398,"twenty":-12.685283,"median":-6.241684,"eighty":-5.176649,"marketCap":434032748},{"date":"2025-09-12","current":-4.331231,"twenty":-12.593229,"median":-6.221845,"eighty":-5.070186,"marketCap":333587089},{"date":"2025-09-19","current":-4.392296,"twenty":-12.449092,"median":-6.213645,"eighty":-5.008506,"marketCap":338290230},{"date":"2025-09-26","current":-10.057984,"twenty":-12.39822,"median":-6.217295,"eighty":-5.008506,"marketCap":774655869},{"date":"2025-10-03","current":-9.721364,"twenty":-12.327968,"median":-6.224236,"eighty":-5.029502,"marketCap":748729706},{"date":"2025-10-10","current":-9.207959,"twenty":-12.309799,"median":-6.253122,"eighty":-5.039662,"marketCap":709187798},{"date":"2025-10-17","current":-7.994552,"twenty":-12.25166,"median":-6.280939,"eighty":-5.051241,"marketCap":615732407},{"date":"2025-10-24","current":-9.364715,"twenty":-12.13417,"median":-6.307461,"eighty":-5.070186,"marketCap":721260982},{"date":"2025-10-31","current":-12.650784,"twenty":-12.13417,"median":-6.352937,"eighty":-5.089294,"marketCap":974350701},{"date":"2025-11-07","current":-13.743232,"twenty":-12.309799,"median":-6.369154,"eighty":-5.142981,"marketCap":1106261420},{"date":"2025-11-14","current":-13.426901,"twenty":-12.512852,"median":-6.477382,"eighty":-5.169369,"marketCap":1080798409},{"date":"2025-11-21","current":-15.07807,"twenty":-12.739549,"median":-6.521866,"eighty":-5.176649,"marketCap":1213709223},{"date":"2025-11-28","current":-19.239461,"twenty":-13.256987,"median":-6.567932,"eighty":-5.191208,"marketCap":1548680395},{"date":"2025-12-05","current":-17.036043,"twenty":-13.72255,"median":-6.589128,"eighty":-5.211681,"marketCap":1371316303},{"date":"2025-12-12","current":-15.859028,"twenty":-13.826268,"median":-6.619611,"eighty":-5.226487,"marketCap":1276572445},{"date":"2025-12-19","current":-15.992906,"twenty":-14.046615,"median":-6.70403,"eighty":-5.26888,"marketCap":1287348998},{"date":"2025-12-26","current":-17.911832,"twenty":-14.268105,"median":-6.806351,"eighty":-5.279538,"marketCap":1441812917},{"date":"2026-01-02","current":-17.59387,"twenty":-14.917986,"median":-6.813207,"eighty":-5.295223,"marketCap":1416218605},{"date":"2026-01-09","current":-17.136452,"twenty":-15.146199,"median":-7.076651,"eighty":-5.307262,"marketCap":1379398717},{"date":"2026-01-16","current":-22.820712,"twenty":-15.452731,"median":-7.200803,"eighty":-5.317689,"marketCap":1836953174},{"date":"2026-01-23","current":-23.646296,"twenty":-15.472295,"median":-7.424882,"eighty":-5.324948,"marketCap":1903408581},{"date":"2026-01-30","current":-20.550355,"twenty":-15.847871,"median":-7.61062,"eighty":-5.334947,"marketCap":1654200805},{"date":"2026-02-05","current":-21.40383,"twenty":-15.958314,"median":-7.92198,"eighty":-5.355906,"marketCap":1722901327}],"updateTime":1770447518254},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"MBX\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2609877055","title":"MBX Biosciences Raises $87 Million in ATM Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2609877055","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609877055?lang=en_us&edition=fundamental","pubTime":"2026-02-06 05:53","pubTimestamp":1770328389,"startTime":"0","endTime":"0","summary":"MBX Biosciences, Inc. ( ($MBX) ) has shared an update. On February 4, 2026, MBX Biosciences, Inc. closed the sale of 2,250,986 shares of its common...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-raises-87-million-in-atm-offering?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/mbx-biosciences-raises-87-million-in-atm-offering?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2609698305","title":"Microbix to Release Q1 2026 Results and Host Investor Webinar on February 12","url":"https://stock-news.laohu8.com/highlight/detail?id=2609698305","media":"TIPRANKS","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2609698305?lang=en_us&edition=fundamental","pubTime":"2026-02-05 21:36","pubTimestamp":1770298617,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) just unveiled an announcement. Microbix Biosystems Inc. will release its financial statements and management disc...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-to-release-q1-2026-results-and-host-investor-webinar-on-february-12?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-to-release-q1-2026-results-and-host-investor-webinar-on-february-12?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","HST","BK4585","BK4007","BK4588","BK4218","BK4181"],"gpt_icon":0},{"id":"2606976710","title":"MBX Biosciences Initiated at Overweight by Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606976710","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606976710?lang=en_us&edition=fundamental","pubTime":"2026-01-28 22:54","pubTimestamp":1769612040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 28, 2026 09:54 ET (14:54 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2606753426","title":"MBX Biosciences initiated with an Overweight at Barclays","url":"https://stock-news.laohu8.com/highlight/detail?id=2606753426","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606753426?lang=en_us&edition=fundamental","pubTime":"2026-01-28 05:31","pubTimestamp":1769549478,"startTime":"0","endTime":"0","summary":"Barclays initiated coverage of MBX Biosciences (MBX) with an Overweight rating and $66 price target Barclays initiated coverage of 12 biotech stock...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-initiated-with-an-overweight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-initiated-with-an-overweight-at-barclays-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX"],"gpt_icon":0},{"id":"2605349914","title":"MBX Biosciences Appoints Laurie Stelzer as Board Director and Audit Committee Chair","url":"https://stock-news.laohu8.com/highlight/detail?id=2605349914","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605349914?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:00","pubTimestamp":1769086827,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. has appointed Laurie Stelzer as an independent director on its Board of Directors and as chairperson of the board's audit committee. Stelzer brings over 25 years of executive and financial leadership experience in the biopharmaceutical industry and has previously served in senior roles at several biotechnology companies.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL24nHw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","IE00BKPKM429.USD","SG9999014005.SGD","SG9999014013.SGD","SG9999014021.USD","LU2210149790.SGD","LU2210150020.SGD","MBX","BK4585","IE00BGHQF748.EUR","BK4588","LU2095319765.USD","BK4112","SG9999014039.USD","IE00B64PRP62.GBP","IE00B3QW5Z07.USD","BK4007","LU0314104364.USD"],"gpt_icon":0},{"id":"2604297011","title":"Is MBX Biosciences’ (MBX) Once‑Monthly Obesity Strategy Quietly Redefining Its Competitive Moat?","url":"https://stock-news.laohu8.com/highlight/detail?id=2604297011","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604297011?lang=en_us&edition=fundamental","pubTime":"2026-01-19 05:16","pubTimestamp":1768770961,"startTime":"0","endTime":"0","summary":"Guggenheim recently reiterated its positive view on MBX Biosciences, highlighting the company’s once-monthly obesity drug MBX 4291 and its plan to advance additional obesity candidates, alongside progress toward Phase 3 trials for lead asset canvuparatide.\nA distinctive aspect of this update is Guggenheim’s focus on MBX’s once-monthly dosing approach in obesity, which could differentiate its pipeline within a crowded weight-loss treatment landscape.\nWe’ll now examine how this emphasis on...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-mbx-biosciences-mbx-oncemonthly-obesity-strategy-quietly","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-mbx-biosciences-mbx-oncemonthly-obesity-strategy-quietly","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2603978909","title":"MBX Biosciences Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2603978909","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603978909?lang=en_us&edition=fundamental","pubTime":"2026-01-16 23:27","pubTimestamp":1768577220,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 16, 2026 10:27 ET (15:27 GMT)","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX"],"gpt_icon":0},{"id":"2603411939","title":"Nasdaq Net Change Percentage Gainers & Losers","url":"https://stock-news.laohu8.com/highlight/detail?id=2603411939","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603411939?lang=en_us&edition=fundamental","pubTime":"2026-01-16 06:30","pubTimestamp":1768516200,"startTime":"0","endTime":"0","summary":"Autozi Internet Tech         AZI      3.62     0.60     19.87    26,510,860. Burning Rock Biotech ADR     BNR     28.52     4.45     18.49        53,550. Innovative Sol & Support    ISSC     22.30     3.05     15.84     2,008,129. Leverage 2X Lg UUUU Dly     UUUG     17.51     2.31     15.23        61,460. Trip.com Group ADR          TCOM     62.78   -12.90    -17.05    33,986,064. Tradr 2X Long APP Daily     APPX     29.04    -5.29    -15.41     2,334,561. GrShr 2x Long RIVN Daily    RVNL     43.80    -7.48    -14.59        83,543. Defiance Tgt 2x Shrt RKLB   RKLZ      2.74    -0.37    -11.90    27,364,202. Direxion Dly SHOP Bull 2X   SHPU     27.51    -3.71    -11.88        53,468. Leverage 2X Lg DUOL Dly     DUOG      9.03    -1.21    -11.83       131,403. Leverage 2x Lg FUTU Dly     FUTG     15.69    -2.01    -11.37        95,781. Only includes stocks with a prior day close of $2 a share. or higher and at least 2,000 shares traded today.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX","NQmain"],"gpt_icon":0},{"id":"2603595006","title":"MBX Biosciences Unveils Canvuparatide Phase 2 Data for Hypoparathyroidism Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2603595006","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603595006?lang=en_us&edition=fundamental","pubTime":"2026-01-14 08:03","pubTimestamp":1768349027,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. has published a presentation outlining key upcoming milestones across its pipeline of precision peptide therapies for endocrine and metabolic diseases. The company plans to initiate a Phase 3 trial for canvuparatide, its investigational once-weekly parathyroid hormone replacement therapy for hypoparathyroidism, in the third quarter of 2026. Results from a one-year open-label extension and additional Phase 2 data are expected in the second quarter of 2026. Other programs include MBX 4291, a GLP-1/GIP candidate with 12-week multiple ascending dose results anticipated in the fourth quarter of 2026, and two additional candidates, MBX 5XXX and MBX 6XXX, with development nominations planned for 2026. The company reports $373.7 million in cash as of December 31, 2025, providing runway into 2029. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT st","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDL9p2YKN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2603163398","title":"MBX Biosciences, Inc. (MBX) Receives a Buy from Stifel Nicolaus","url":"https://stock-news.laohu8.com/highlight/detail?id=2603163398","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603163398?lang=en_us&edition=fundamental","pubTime":"2026-01-13 22:46","pubTimestamp":1768315577,"startTime":"0","endTime":"0","summary":"In a report released today, Annabel Samimy from Stifel Nicolaus maintained a Buy rating on MBX Biosciences, Inc., with a price target of $50.00. Ac...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/mbx-biosciences-inc-mbx-receives-a-buy-from-stifel-nicolaus-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/mbx-biosciences-inc-mbx-receives-a-buy-from-stifel-nicolaus-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4127","SF","MBX","BK4007"],"gpt_icon":0},{"id":"2602563511","title":"MBX Biosciences provides update on clinical programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2602563511","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602563511?lang=en_us&edition=fundamental","pubTime":"2026-01-12 06:20","pubTimestamp":1768170041,"startTime":"0","endTime":"0","summary":"MBX Biosciences (MBX) announced it will provide an update on its clinical programs, expanding obesity pipeline, and outlook for 2026 during the Com...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-provides-update-on-clinical-programs-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/mbx-biosciences-provides-update-on-clinical-programs-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2602683415","title":"BRIEF-Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602683415","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602683415?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:04","pubTimestamp":1768165448,"startTime":"0","endTime":"0","summary":"BRIEF-Mbx Biosciences Says Phase 3 Trial Of Canvuparatide To Start In Q3 2026Jan 11 (Reuters) - MBX Biosciences Inc MBX.O:MBX BIOSCIENCES TO PROVIDE 2026 OUTLOOK AND BUSINESS UPDATE AT 44TH ANNUAL J.P","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUATNCVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2602568364","title":"MBX Biosciences Projects Cash Reserves Will Fund Operations Into 2029","url":"https://stock-news.laohu8.com/highlight/detail?id=2602568364","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602568364?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165210,"startTime":"0","endTime":"0","summary":"MBX Biosciences Inc. reported a strong financial outlook, with preliminary unaudited cash, cash equivalents, and marketable securities totaling approximately $373.7 million as of December 31, 2025. The company expects this cash position to fund its operations into 2029. No significant variations in business performance were disclosed for the period.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. MBX Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire  on January 11, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nNDL5RbM97:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014005.SGD","BK4588","BK4112","IE00B3QW5Z07.USD","LU0314104364.USD","LU2095319765.USD","NDAQ","SG9999014039.USD","BK4007","SG9999014021.USD","LU2210149790.SGD","MBX","SG9999014013.SGD","BK4585","IE00B64PRP62.GBP","IE00BGHQF748.EUR","IE00BKPKM429.USD","LU2210150020.SGD"],"gpt_icon":0},{"id":"2602956839","title":"Mbx Biosciences Inc - Phase 3 Trial of Canvuparatide to Start in Q3 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602956839","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602956839?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUATNCVP:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2602683505","title":"Mbx Biosciences to Provide 2026 Outlook and Business Update at 44TH Annual J.p. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602683505","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602683505?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165202,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUATNCVP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2602343568","title":"Mbx Biosciences Inc - Two New Obesity Candidates to Be Nominated in 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2602343568","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602343568?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165202,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260111:nTUATNCVP:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","MBX"],"gpt_icon":0},{"id":"2602686805","title":"MBX Biosciences to Provide 2026 Outlook and Business Update at 44th Annual J.P. Morgan Healthcare Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2602686805","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602686805?lang=en_us&edition=fundamental","pubTime":"2026-01-12 05:00","pubTimestamp":1768165200,"startTime":"0","endTime":"0","summary":"One-year follow-up data from Phase 2 trial of once-weekly canvuparatide, a potential best-in-class therapy for hypoparathyroidism, anticipated in Q2 2026; Phase 3 initiation on track for Q3 2026 12-we","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/01/11/3216493/0/en/MBX-Biosciences-to-Provide-2026-Outlook-and-Business-Update-at-44th-Annual-J-P-Morgan-Healthcare-Conference.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0314104364.USD","LU1074936037.SGD","BK4504","LU0795875086.SGD","LU0158827781.USD","XBI","LU0320765646.SGD","BK4581","LU1244550577.SGD","LU2023251221.USD","XLV","IE00BKVL7J92.USD","BK4137","PBH","BK4588","LU2271345857.HKD","LU1244550221.USD","LU1548497426.USD","BK4516","LU0528227936.USD","HCSG","LU0795875169.SGD","BK4585","LU1363072403.SGD","LU1668664300.SGD","LU2347655156.SGD","LU1791710582.SGD","IE00BZ1G4Q59.USD","HP","LU0106261372.USD","LU2111349929.HKD","LU0234570918.USD","LU0882574139.USD","LU2133065610.SGD","MBX","LU0128526141.USD","LU0225283273.USD","LU0098860793.USD","LU0557290698.USD","LU2028103732.USD","LU2089284900.SGD","LU0106831901.USD","LU1989772923.USD","LU0267386448.USD","LU0158827948.USD","LU1791710400.SGD","LU1720051108.HKD","LU0029874061.USD","LU1162221912.USD","LABU"],"gpt_icon":0},{"id":"2602830617","title":"Is UBS’s Canvuparatide Focus Altering The Investment Case For MBX Biosciences (MBX)?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602830617","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602830617?lang=en_us&edition=fundamental","pubTime":"2026-01-10 02:43","pubTimestamp":1767984186,"startTime":"0","endTime":"0","summary":"UBS recently initiated coverage on MBX Biosciences with a Buy rating, highlighting the company’s pipeline of long-acting therapies for metabolic and endocrine diseases, including once-weekly canvuparatide and a monthly GLP-1 obesity program.\nThe focus on upcoming clinical milestones for these programs, underpinned by MBX Biosciences’ strong liquidity and zero debt, has sharpened investor attention on its R&D-driven business model.\nWe’ll now examine how UBS’s emphasis on MBX Biosciences’...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-ubss-canvuparatide-focus-altering-the-investment-case-for","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-mbx/mbx-biosciences/news/is-ubss-canvuparatide-focus-altering-the-investment-case-for","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2602376497","title":"Microbix Tightens EBITDA Disclosure After OSC Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2602376497","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602376497?lang=en_us&edition=fundamental","pubTime":"2026-01-09 21:15","pubTimestamp":1767964558,"startTime":"0","endTime":"0","summary":"Microbix Biosystms ( ($TSE:MBX) ) has issued an update. Microbix Biosystems Inc., a Canadian life sciences manufacturer specializing in antigens, q...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/microbix-tightens-ebitda-disclosure-after-osc-review?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/microbix-tightens-ebitda-disclosure-after-osc-review?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["MBX","BK4007"],"gpt_icon":0},{"id":"2601386691","title":"MBX Biosciences Initiated at Buy by UBS","url":"https://stock-news.laohu8.com/highlight/detail?id=2601386691","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2601386691?lang=en_us&edition=fundamental","pubTime":"2026-01-08 04:33","pubTimestamp":1767817980,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/MBX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 07, 2026 15:33 ET (20:33 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MBX","BK4007"],"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":1,"totalSize":118,"code":"91000000","status":"200"}]}}